MicroPort Orthopedics Announces Industry Symposium at American Association of Hip and Knee Surgeons

Posted On October 19, 2017 By OrthoSpineNews In Recon /

ARLINGTON, TENNESSEE, October 17, 2017 – MicroPort Orthopedics, a medical device company that develops and manufactures cutting-edge joint replacement implants and approaches, will host an industry symposium at the annual American Association of Hip and Knee Surgeons (AAHKS) meeting titled, “Tackling Your Toughest Cases in the Changing Healthcare Landscape” on Friday, November 3, 2017.

The symposium will feature four surgeon panelists, invited by MicroPort Orthopedics, who will discuss management of the toughest hip and knee replacement cases in an orthopedic landscape that faces evolving healthcare trends including new orthopedic technology and innovation, changing regulations and payment models, and the shift to outpatient care.

“Everyone in the medical device industry recognizes that the healthcare marketplace is evolving at breakneck speed, and we are constantly in pursuit of better and more efficient ways to adapt to these changes,” said Aurelio Sahagun, President, MicroPort Orthopedics. “We’re grateful to have not only a platform at AAHKS to discuss these innovations but also four renowned orthopedic surgeons who can speak to industry trends, best practices, and new approaches to their work.”

The symposium will be moderated by Stephen Murphy, MD, an orthopedic surgeon at New England Baptist Hospital, who will also be speaking about his experience in the Bundled Payments for Care Improvement (BPCI) Initiative. Joining Dr. Murphy will be, Judd Cummings, MD, Jimmy Chow, MD and Nicolas Noiseux, MD, MS, FRCSC. Dr. Cummings, an orthopedic surgeon at Specialty Orthopedic Surgery, will examine key considerations when taking on tough cases. Dr. Chow, a hip & knee specialist at Chow Hip and Knee, will discuss the importance of powerful surgical philosophy for Total Hip Arthroplasty. Dr. Noiseux, an associate professor in the department of Orthopedics and Rehabilitation at the University of Iowa Hospitals and Clinics, will be talking about anterior-posterior stability in complex primary cases. Following the discussion, the surgeons will answer questions asked by the audience.

About MicroPort Orthopedics

Established in January 2014, MicroPort Orthopedics Inc. is the fifth largest multinational producer of hip and knee implants and a proud member of the MicroPort Scientific Corporation family of companies. From its headquarters in Arlington, Tennessee, MicroPort Orthopedics develops, produces, and distributes innovative OrthoRecon products. The company’s U.S.-based manufacturing and logistics capabilities deliver high quality hip and knee products to patients and their doctors in over 60 countries, including the U.S., EMEA, Japanese, Latin American and China markets. For more information about MicroPort Orthopedics, visit http://www.ortho.microport.com/ or follow the company on Twitter at @MicroPortOrtho.

About MicroPort Scientific

MicroPort Scientific Corporation is a leading medical device company focused on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, MicroPort maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort is dedicated to becoming a patient-oriented global enterprise that improves and reshapes patient lives through application of innovative science and technology. For more information, please refer to: http://www.microport.com.

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words “believe,” “intend,” “expect,” “anticipate,” “project,” “estimate,” “predict,” “is confident,” “has confidence” and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort’s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

Ryan Donovan | Assistant Account Executive

O: 617-374-8800 x102

M: 857-294-2561

Email: rdonovan@lavoiehealthscience.com | Twitter: @lavoiegroup
LinkedIn: https://www.linkedin.com/company/lavoie-group

Website: http://www.lavoiehealthscience.com

DSM Biomedical and Cerapedics partner for peptide enhanced bone graft

Posted On October 18, 2017 By OrthoSpineNews In Biologics /

October 17, 2017 By Danielle Kirsh

DSM Biomedical has partnered with Cerapedics to create and manufacture the next generation of peptide-enhanced bone graft.

The partnerships allows for DSM’s regenerative materials capabilities to be used with Cerapedics’s proprietary synthetic small peptide (P-15) technology developed by Cerapedics.

Designed for fast and predictable remodeling in bone graft substitute applications, DSM’s newest bioceramic platform is make of a carbonated apatite matrix. The partnership states that DSM will provide collagen carrier, final packaging and full support throughout the product development process.

“The partnership combines the industry leading expertise and capabilities in bioceramic materials of DSM with Cerapedics’ innovative growth factor, delivering a new product solution to improve people’s lives,” David Yonce, VP and global head of innovation at DSM Biomedical, said. “Together, from concept to commercialization, we are at the leading edge of advanced healing solutions.”

READ THE REST HERE

NuVasive Launches New 3D-Printed Porous Titanium Implant In Expanding Advanced Materials Science Portfolio

Posted On October 18, 2017 By OrthoSpineNews In Spine /

SAN DIEGO, Oct. 18, 2017 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced the launch of Modulus® XLIF® titanium implants. The new 3D-printed, fully porous device provides a differentiated offering for the Company’s flagship XLIF procedure, highlighting a continued commitment to innovation in developing first-of-its-kind technology to support its leading lateral spine procedure.

The new Modulus titanium implants are developed using additive manufacturing technology, or 3D printing, to create an organic, porous architecture that mimics the porosity and stiffness of bone for reduced stress shielding. By employing advanced microporous surface topography, Modulus XLIF creates an ideal environment for bone in-growth¹. The device’s optimized architecture also leads to improved imaging characteristics compared to traditional titanium interbody devices.

“We’ve seen an increase in surgeon preference to use titanium interbody options in spine surgeries, and we were confident we could develop a titanium option that delivers the porous properties surgeons need,” said Matt Link, executive vice president of strategy, technology and corporate development of NuVasive. “Modulus XLIF maximizes the potential of 3D-printed spinal implants through the application of unique and advanced software optimization processes. This product launch further represents our continued commitment to advancing surgical materials, and delivering best-in-class implants that provide superior osseointegration and biomechanics.”

Modulus XLIF’s novel technology represents an advancement in the growing titanium interbody market. The implant expands the offerings used in the XLIF procedure, the only lateral approach spine procedure proven with over 15 years of clinical evidence and 400 peer-reviewed lateral-approach, XLIF specific publications.

“Surface architecture is an increasingly important part of the fusion process,” said Kade Huntsman, MD, orthopedic spine surgeon with the Salt Lake Orthopaedic Clinic in Salt Lake City, Utah. “The design of Modulus XLIF maximizes the potential of additive manufacturing through the combination of highly porous endplates with an optimized internal structure.”

NuVasive will showcase its market-leading, procedurally-integrated technologies, including the new Modulus XLIF in NuVasive Booth #713 at the North American Spine Society Annual Meeting held October 25-28, 2017 in Orlando, Fla.

About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is transforming spine surgery and beyond with minimally invasive, procedurally-integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company’s portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With $962 million in revenues (2016), NuVasive has an approximate 2,300 person workforce in more than 40 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.

Forward-Looking Statements
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA™ platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

¹Preclinical data on file. Data may not be representative of clinical results.

SOURCE NuVasive, Inc.

American Surgical Team Successfully Completes First 3D Printed Titanium and Polymer Sternum Implant Procedure in the United States

Posted On October 18, 2017 By OrthoSpineNews In Spine, Top Stories /

October 18, 2017

NEW YORK: On August 2, 2017, an American surgical team conducted a surgery to replace the sternum and partial ribcage of a 20 year-old woman using a custom 3D-printed composite titanium/porous polyethylene implant. It is the first time this technology has been used in the United States and only the second time in the world that a 3D-printed composite sternum and ribcage has been implanted.

The implant was designed and created for a patient named Penelope Heller by Anatomics, an Australian company that specializes in the manufacture of patient specific implants for surgeons around the world, and was made available to the patient via the United States Food & Drug Administration’s (FDA) Expanded Access (Compassionate Use) Program. Anatomics’ custom 3D printed implants do not have marketing approval in the US. The FDA’s Expanded Access Program provides a path to accessing devices for patients whom the treating physician believes may provide a benefit, but have not received FDA marketing approval.

The surgical team, led by Jeffrey L. Port M.D., attending cardiothoracic surgeon at NewYork-Presbyterian/Weill Cornell Medical Center and professor of clinical cardiothoracic surgery at Weill Cornell Medicine, undertook the operation to revise a prior sternum/ribcage removal and reconstruction conducted in 2014. The patient underwent the original procedure to remove a malignant bone tumor after she was diagnosed with chondrosarcoma, a rare cancer affecting the bones and joints that is resistant to chemotherapy and radiotherapy and requires surgical removal.

In the original resection surgery, the cancer was successfully removed and the previous surgeon created an implant for the patient, using off-the-shelf Gore-Tex (low-density porous polytetrafluoroethylene, or PTFE) and Bone Cement (methyl methacrylate, or MMC). Afterward, the patient was cancer-free but continued to experience pain and issues with breathing that did not improve with time. Online research led the patient to a similar surgery performed in Spain using a custom implant also developed by Anatomics. The patient and her family then worked with the staff at NewYork-Presbyterian/Weill Cornell Medical Center and Anatomics to access the implant under the FDA’s Expanded Access program.

The custom implant was designed using high-resolution CT scans of the patient’s chest that were sent to Anatomics engineers via the secure AnatomicsRx software platform. After Dr. Port reviewed and confirmed the design on-line with the engineers, a biomodel of the patient’s sternum and ribcage was created and a build code was sent to Australia’s Commonwealth Scientific & Industrial Research Organisation’s (CSIRO) 3D printing laboratory, Lab 22. The patient’s custom sternum implant is the second in the world to also use Anatomics’ PoreStar technology, a proprietary porous polyethylene material with bone-like architecture. PoreStar is currently awaiting FDA marketing approval.

“After my initial resection and reconstruction surgery, I continued to experience breathing issues and pain,” said Ms. Heller. “With a long, active life ahead of me, I wanted to participate in activities that I love fully and without pain. Electing to have this procedure was a big decision, and I’m coming forward to empower other people in the same position.”

Anatomics’ Executive Chairman Paul D’Urso, MBBS (Hons) Ph.D. FRACS said, “Anatomics is humbled by the strength of the thousands of patients we have helped over 25 years since inventing BioModeling technology. The patient’s story is one of many, but what makes it truly remarkable is how the patient and her family, Dr. Port and the staff at NewYork-Presbyterian/Weill Cornell, Anatomics, and the FDA came together to make this story a reality. It was a group effort that began with the patient’s pursuit of information.”

About Anatomics

Anatomics is an Australian medical device company that has been manufacturing and marketing surgical products to surgeons locally and internationally since 1996. Anatomics pioneered CT scan derived surgical implant technology and was first to market with an innovative, quality product that assists surgeons to produce better surgical outcomes and reduce expensive operating time. For more information, visit http://www.anatomics.com and follow the company on twitter at https://twitter.com/anatomicsrx.

For further information contact:

(Media) Tiberend Strategic Advisors, Inc

Janine McCargo, Senior Vice President

Telephone: +1 (646) 604-5150

e-mail: jmccargo@tiberend.com

Anatomics United States

Dr. Dean Carson, Vice President US Operations

951 Mariners Island Blvd. San Mateo, CA 94404 (CSIRO Office)

Telephone: +1 (415) 806-2599

e-mail: dean.carson@anatomics.com

Anatomics Australia

Dr. Paul D’Urso, Executive Chairman

Suite 1, 23-27 Wellington Street, St Kilda, Victoria, 3182, Australia

Telephone: +61 3 9529-8088

e-mail: contact@anatomics.com

Life Spine Announces Alpha Release of the SENTRY™ ALIF Plating System

Posted On October 18, 2017 By OrthoSpineNews In Spine, Top Stories /

October 18, 2017

HUNTLEY, Ill.–(BUSINESS WIRE)–Life Spine, a medical device company that designs, develops, manufactures, and markets products for the surgical treatment of spinal disorders today announced the Alpha launch of the SENTRY ALIF Plating System.

SENTRY ALIF is a plating system designed to eliminate the need for posterior stabilization with anterior lumbar interbody fusion. The low profile plate design provides a rigidly stable construct without disturbing surrounding vasculature. An Anterior Lumbar Interbody Fusion prevents the need to disturb the muscles of the lower back potentially reducing post-operative pain and complications.

The SENTRY ALIF system incorporates a Cam style locking mechanism, which provides visual, tactical, and audible feedback to prevent screw back out. This innovative and proven feature allows for easy screw removal and repositioning of the plate for streamlined surgeon usage. SENTRY ALIF has an S1 anchor ledge feature to accommodate L5-S1 surgical procedures, which provides better guidance for proper positioning of the plate.

Mariusz Knap, Vice President of Global Marketing and Business Development noted, “We are thrilled to launch the SENTRY ALIF Plating System and add to our Anterior Lumbar solutions portfolio. We have had great success with predicate devices that incorporate the Cam style locking mechanism. It made perfect sense to add the same technology to an anterior lumbar plate. SENTRY ALIF’s low profile design and multiple plate options strengthen Life Spine’s commitment to providing differentiated products to surgeons and their patients.”

About Life Spine

Life Spine is dedicated to improving the quality of life for spinal patients by increasing procedural efficiency and efficacy through innovative design, uncompromising quality standards, and the most technologically advanced manufacturing platforms. Life Spine, which is privately held, is based in Huntley, Illinois. For more information, please visit: http://www.lifespine.com.

Life Spine is a registered trademark.

Contacts

Life Spine
Mr. Omar Faruqi
Chief Financial Officer
ofaruqi@lifespine.com
847-884-6117

Medovex Corporation to Participate in World’s Largest Spine Exhibition, NASS 2017

Posted On October 18, 2017 By OrthoSpineNews In Spine /

ATLANTA, GA — (Marketwired) — 10/18/17 — Medovex Corp. (NASDAQ:MDVX) (“Medovex” or the “Company”), the developer of the DenerveX® System, a new and novel device designed for enduring relief of Facet Joint Syndrome related to back pain, today announced the Company will be participating in NASS 2017, being held in Orlando, Florida, October 25-28, 2017.

The North American Spine Society (“NASS”) is a one of a kind annual meeting where spine care professionals from around the globe will share the latest information, innovative techniques and procedures, best practices, and new technologies.

A copy of the Company’s invitation to The Surgical Innovation Cadaver Lab may be found at the following link: Medovex Invitation

The lab will be led leading spine surgeons and key opinion leaders including Vik Kapoor, MD, Manchester, UK, Martin Deeg, MD, Stuttgart, Germany, Jan Spiller, MD, Stenum-Bremen, Germany, and Gabriel Davila, MD, Medellin, Columbia.

Manfred Sablowski, Medovex Sr. Vice President of Sales and Marketing, stated, “We are excited to again participate at NASS. We developed the DenerveX System to enhance a patient’s quality of life. The agony of pain associated with the Facet Joint can be life-altering, robbing people of even the simplest joys of daily life like bending over to hug a grandchild, taking a walk or gardening. Powerful painkillers often prescribed for severe back pain are fanning the flames of the nation’s opioid epidemic. The DenerveX System involves a simple, minimally invasive, ‘keyhole’ procedure that is designed to bring faster, longer-lasting relief.”

Videos of leading spine surgeon Dr. Vik Kapoor talking about FJS and the DenerveX Device may be viewed at the following links:

https://youtu.be/6Q7hpEsF2mg

https://youtu.be/GIgPaIenXp4

Facet Joint Syndrome (FJS), also known as spinal osteoarthritis, spinal arthritis, or facet joint osteoarthritis, is a significant health and economic problem in the United States and other countries in the EU and Rest of World affecting millions each year. Current treatment options are generally temporary and there is no proven long-lasting option for FJS.

The DenerveX System is a highly differentiated technology. It denervates and removes capsular tissue from the Facet Joint in one single procedure. Treatment results from the combined effect of a deburring or polishing action and RF ablation treatment on the Facet Joint. Using this new technique, the slowly rotating burr removes the targeted facet joint synovial membrane and joint surface while the heat ablation destroys tissue and denudes any residual nervous and synovial membrane overlying the joint, removing the end point sensory tissue of the joint.

The DenerveX System consists of the DenerveX Kit which contains the DenerveX Device, a single use medical device and the DenerveX Pro-40 Power Generator. DenerveX system is CE marked and for sale in countries outside the US accepting the CE mark, but is not yet FDA cleared.

Please also follow us on Facebook at https://www.facebook.com/medovex/.

About Medovex

Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company’s first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com

Safe Harbor Statement

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the Securities and Exchange Commission (the “SEC”), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

CONTACT INFORMATION

Medovex Corp.

Jason Assad

470-505-9905

Jassad@medovex.com

Amedica Receives Positive Nasdaq Listing Decision

Posted On October 18, 2017 By OrthoSpineNews In Financial /

SALT LAKE CITY, Oct. 17, 2017 (GLOBE NEWSWIRE) — Amedica Corporation (Nasdaq: AMDA) (the “Company”), an innovative biomaterial company that develops and manufactures silicon nitride as a platform for biomedical applications, announced today that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request for an extension within which to evidence full compliance with the criteria for continued listing on The Nasdaq Capital Market, including the filing requirement and the $1.00 closing bid price requirement. The Company’s continued listing on Nasdaq is subject to the Company filing its Forms 10-Q for the quarterly periods ended March 31, 2017 and June 30, 2017 with the SEC by October 31, 2017, and the Company evidencing a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days by November 30, 2017. The Company expects to timely satisfy the deadlines set forth in the Panel’s decision.

The Company is diligently working to evidence full compliance with all applicable requirements for continued listing on The Nasdaq Capital Market; however, there can be no assurance that the Company will regain compliance with the applicable criteria within the period of time granted by the Panel.

About Amedica Corporation
Amedica is focused on the development and application of medical-grade silicon nitride ceramics. Amedica markets spinal fusion products and is developing a new generation of wear- and corrosion-resistant implant components for hip and knee arthroplasty. The Company manufactures its products in its ISO 13485 certified manufacturing facility and, through its partnership with Kyocera, the world’s largest ceramic manufacturer. Amedica’s spine products are FDA-cleared, CE-marked, and are currently marketed in the U.S. and select markets in Europe and South America through its distributor network and its OEM partnerships.

For more information on Amedica or its silicon nitride material platform, please visit www.amedica.com.

Forward-Looking Statements

This press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties. For example, there can be no assurance that we will regain compliance with the applicable criteria within the period of time granted by the Panel and that we will be able to maintain our listing on any NASDAQ market. Other factors that could cause actual results to differ materially from those contemplated within this press release can also be found in Amedica’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on September 20, 2017, and in Amedica’s other filings with the SEC. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

Contact:
Amedica IR 
801-839-3502
IR@amedica.com

B9317486112Z.1_20150526215552_000_GARAT8EII.1-0-1.jpg

Arthrex Announces Plans for New Surgical Device Manufacturing Facility

Posted On October 18, 2017 By OrthoSpineNews In Extremities, Top Stories /

NAPLES, FL – October 16, 2017 – Arthrex announced plans Monday to build a state-of-the-art surgical device and implant manufacturing facility in Anderson County, South Carolina.

Construction on the $30 million, 200,000-square-foot facility is scheduled to begin in the first quarter of 2018 with completion by early 2019.

“This investment is part of Arthrex’s global expansion plan to support the growth and development of new and innovative products that help surgeons treat their patients better,” said Andy Owen, Arthrex Vice President of Manufacturing. “It also represents our continued commitment to manufacturing quality products in the United States.”

The Anderson facility will be Arthrex’s fourth U.S.-based manufacturing facility. The others are located in Ave Maria, FL, Santa Barbara, CA and City of Industry, CA.

Arthrex plans to work with Tri-County Technical College in Anderson to develop a strong pipeline of qualified manufacturing personnel, utilizing their in-depth programs and long-standing relationships with institutions like Clemson University that are dedicated to supporting the manufacturing industry.

“Arthrex is pleased to bring its innovative spirit and unique culture to South Carolina and we look forward to leveraging the outstanding work done in the area to prepare future employees for high-level manufacturing jobs,” Owen said.

The construction of the Anderson facility will not affect operations or employees in Southwest Florida or California, and Owen reiterated that Arthrex is committed to its future growth, job creation and investment in Southwest Florida. This includes a significant expansion project at its corporate headquarters in North Naples scheduled to begin in the first quarter of 2018, as well as partnering with community leaders to develop advanced manufacturing training programs in Collier County.

About Arthrex

Arthrex Inc., headquartered in Naples, FL, is a global leader in orthopedic product development and medical education for orthopedic surgeons. More than 11,000 products for arthroscopic and minimally invasive orthopedic surgical procedures have been developed by Arthrex and are currently marketed worldwide. For more information, visit www.Arthrex.com.

Category: Corporate Press Releases

American Academy of Orthopaedic Surgeons (AAOS) to launch family of orthopaedic registries

Posted On October 17, 2017 By OrthoSpineNews In Recon, Top Stories /

ROSEMONT, Ill., Oct. 17, 2017 /PRNewswire-USNewswire/ — The American Academy of Orthopaedic Surgeons (AAOS) today announced plans to create a national family of clinical data registries for a broad range of orthopaedic conditions and procedures. As part of this effort, the American Joint Replacement Registry (AJRR) is integrating into the AAOS effective immediately. The AJRR, a national hip and knee joint replacement registry with 970 participating U.S. hospitals and 40 ambulatory surgery centers, has captured and analyzed data on more than one million procedures since its creation in 2010.

The launch of the new registry program reflects the Academy’s strategic commitment to quality.

“A central group of orthopaedic registries, providing standardized and consistent data, will allow us to optimally measure performance and value, create and recommend informed reimbursement and treatment standards, develop education programs that address practice and treatment deficiencies, and most importantly, continually and collectively improve patient safety, treatment and outcomes,” said AAOS President William J. Maloney, MD.

“We welcome AJRR to our registry family,” added Dr. Maloney. “Their success and standards will serve as the cornerstone of our new program.”

“The Academy and AJRR share a commitment to helping orthopaedic surgeons provide the highest quality musculoskeletal care to patients,” said AJRR Board of Directors Chair Daniel J. Berry, MD. “This new integration will allow us to expand and enhance our data collection capacity. We look forward to a continuing, seamless relationship with our partners and participating facilities as we move forward.”

Nathan Glusenkamp is the new AAOS director of orthopaedic registries. Glusenkamp previously served as president of provider solutions at FIGmd, a rapidly growing health information technology vendor delivering data liquidity interfaces to medical societies and boards. Prior to joining FIGmd, he oversaw the American College of Cardiology’s PINNACLE Registry, the largest observational outpatient cardiovascular registry in the world.

The AJRR will serve as the hip and knee registries for AAOS, continue to operate business as usual without interruption for existing participating sites, and retain the AJRR name. Additional AAOS registries will launch beginning in mid-to-late 2018, and over the next five years, covering a broad range of conditions and procedures and including data from outpatient and in-patient settings.

More Information about the AAOS
With more than 38,000 members, the American Academy of Orthopaedic Surgeons is the world’s largest medical association of musculoskeletal specialists. The AAOS provides educational programs for orthopaedic surgeons and allied health professionals, champions and advances the highest quality musculoskeletal care for patients, and is the authoritative source of information on bone and joint conditions, treatments and related issues.

Visit AAOS, at:
Newsroom.aaos.org for bone and joint health news, stats, facts, images and interview requests.
ANationinMotion.org for inspirational patient stories, and orthopaedic surgeon tips on maintaining bone and joint health, avoiding injuries, treating musculoskeletal conditions and navigating recovery.
Orthoinfo.org for patient information on hundreds of orthopaedic diseases and conditions.
Facebook.org/AAOS1
Twitter.com/AAOS1

More information about AJRR
The American Joint Replacement Registry is a multi-stakeholder, independent organization for data collection and quality improvement initiatives for total hip and knee replacements. AJRR’s goal is to optimize patient outcomes through collection of data on all primary and revision total joint replacement procedures in the U.S. Today, the Registry contains more than 1,000,000 procedures from over 8,000 surgeons. For more information about AJRR, visit www.ajrr.net

SOURCE American Academy of Orthopaedic Surgeons

Lamar Alexander and Patty Murray announce bipartisan Senate deal to prop up Obamacare

Posted On October 17, 2017 By OrthoSpineNews In Regulatory, Top Stories /

Deborah Barfield Berry, USA TODAY/October 17, 2017

WASHINGTON — Democratic and Republican leaders in the Senate announced they have reached a bipartisan deal to shore up the Affordable Care Act health insurance markets for two years while Congress continues to grapple with GOP efforts to replace the law.

Sens. Lamar Alexander, R-Tenn., and Patty Murray, D-Wash., the leaders of the Senate health committee, said Tuesday they have struck a deal for a two-year extension of subsidies for insurance companies to cover low-income clients — subsidies that President Trump canceled last week.

Alexander told reporters the deal would also expand authority for states to experiment with alternative standards for insurance plans that deviate from federal requirements, but it would not do away with the requirement to cover people with pre-existing conditions. The deal would also not eliminate so-called essential health benefits — such as mental health and maternity care — that insurance plans must cover.

Republican efforts to repeal Obamacare ran aground in part because of concerns of both Democrats and Republicans that these provisions would be eliminated.

The agreement would involve a two-year extension of federal payments to insurers that Trump halted last week. Unless the money is quickly restored, insurers and others say that will result in higher premiums for people buying individual policies and in some carriers leaving unprofitable markets.

“This agreement avoids chaos,” Alexander said. “Over the next two years, I think, Americans won’t have to worry about the price of health (insurance) and being able to buy insurance in the counties where they live.”